Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma
The purpose of this study is to determine whether the immunostimulating agent CpG-ODN is effective in the treatment of glioblastoma
Glioblastoma
DRUG: CpG-ODN
Survival, 2 years
Progression-free survival, 2 years|Tolerance, 2 years
The purpose of this study is to determine whether the immunostimulating agent CpG-ODN is effective in the treatment of glioblastoma